A Retrospective Analysis of Quetiapine in the Treatment of Pervasive Developmental Disorders

Adam H. Corson, BA; John E. Barkenbus, MD; David J. Posey, MD;Kimberly A. Stigler, MD; and Christopher J. McDougle, MD

Published: November 1, 2004

Article Abstract

Background: The purpose of this study was to examine the effectiveness and tolerability of quetiapine for aggression, hyperactivity, and self-injury in pervasive developmental disorders (PDDs).

Method: The medical records of all patients with PDDs diagnosed according to DSM-IV criteria and treated with quetiapine were retrospectively reviewed. Patients who received quetiapine for at least 4 weeks and who were not concurrently treated with another antipsychotic or mood stabilizer were included. Improvement was measured with the Clinical Global Impressions-Improvement scale (CGI-I), with response determined by ratings of “much improved” or “very much improved.” Data were collected from May 15, 2003 through November 30, 2003.

Results: Of 857 records reviewed, 20 patients (16 male, 4 female) (mean ± SD age = 12.1 ± 6.7 years; range, 5-28 years) received a quetiapine trial (mean ± SD dosage = 248.7 ± 198.4 mg/day; range, 25-600 mg/day) over a mean duration of 59.8 ± 55.1 weeks (range, 4-180 weeks). Eight (40%) of 20 patients were judged “responders” to quetiapine; the mean CGI-I score for the entire group was 3.0 ± 1.1 (minimally improved). A statistically significant improvement (p = .002) was found between a mean pretrial CGI-Severity of Illness scale (CGI-S) score of 5.1 ± 0.6 (markedly ill) and a posttrial CGI-S score of 4.2 ± 1.1 (moderately ill). Adverse effects occurred in 50% (N = 10) of patients and led to drug discontinuation in 15% (N = 3) of patients.

Conclusion: Quetiapine was modestly effective for maladaptive behavior in patients with a PDD. Controlled studies are needed to further assess these preliminary findings.

Volume: 65

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...